COPENHAGEN, Denmark, April 20, 2010 (GLOBE NEWSWIRE) -- GlaxoSmithKline (GSK) and Genmab A/S (OMX:GEN) confirmed today that the European Commission (EC) has granted a conditional marketing authorization for Arzerra™ (ofatumumab) for the treatment of refractory chronic lymphocytic leukemia (CLL). Ofatumumab is indicated for the treatment of CLL in patients who are refractory (have not responded) to fludarabine and alemtuzumab. Fludarabine and alemtuzumab are standard therapies currently used to treat CLL.
